Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 217

1.

Periprocedural Stroke and Myocardial Infarction as Risks for Long-Term Mortality in CREST.

Jones MR, Howard G, Roubin GS, Blackshear JL, Cohen DJ, Cutlip DE, Leimgruber PP, Rhodes D, Prineas RJ, Glasser SP, Lal BK, Voeks JH, Brott TG; CREST Investigators.

Circ Cardiovasc Qual Outcomes. 2018 Nov;11(11):e004663. doi: 10.1161/CIRCOUTCOMES.117.004663.

PMID:
30571337
2.

Benefit and Risk of Prolonged DAPT After Coronary Stenting in Women.

Berry NC, Kereiakes DJ, Yeh RW, Steg PG, Cutlip DE, Jacobs AK, Abbott JD, Hsieh WH, Massaro JM, Mauri L; DAPT Study Investigators.

Circ Cardiovasc Interv. 2018 Aug;11(8):e005308. doi: 10.1161/CIRCINTERVENTIONS.117.005308.

PMID:
30354781
3.

Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients.

Roguin A, Kandzari DE, Marcusohn E, Koolen JJ, Doros G, Massaro JM, Garcia-Garcia HM, Bennett J, Gharib EG, Cutlip DE, Waksman R.

Circ Cardiovasc Interv. 2018 Oct;11(10):e007331. doi: 10.1161/CIRCINTERVENTIONS.118.007331.

PMID:
30354631
4.

Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents.

Kandzari DE, Koolen JJ, Doros G, Massaro JJ, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R; BIOFLOW V Investigators.

J Am Coll Cardiol. 2018 Dec 25;72(25):3287-3297. doi: 10.1016/j.jacc.2018.09.019. Epub 2018 Sep 23.

5.

Mortality After Percutaneous Coronary Intervention: Narrowing the Knowledge Gap.

Cutlip DE, Fischman DL.

Circ Cardiovasc Interv. 2018 Jul;11(7):e007008. doi: 10.1161/CIRCINTERVENTIONS.118.007008. No abstract available.

PMID:
30006335
6.

Defining Staged Procedures for Percutaneous Coronary Intervention Trials: A Guidance Document.

Spitzer E, McFadden E, Vranckx P, de Vries T, Ren B, Collet C, Onuma Y, Garcia-Garcia HM, Lopes RD, Stone GW, Cutlip DE, Serruys PW.

JACC Cardiovasc Interv. 2018 May 14;11(9):823-832. doi: 10.1016/j.jcin.2018.03.044. Review.

PMID:
29747912
7.

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials.

Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Thanh Hai MT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O'Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ; Standardized Data Collection for Cardiovascular Trials Initiative (SCTI).

J Am Coll Cardiol. 2018 Mar 6;71(9):1021-1034. doi: 10.1016/j.jacc.2017.12.048. Review.

8.

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials.

Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Hai MTT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O'Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ; Standardized Data Collection for Cardiovascular Trials Initiative (SCTI).

Circulation. 2018 Feb 27;137(9):961-972. doi: 10.1161/CIRCULATIONAHA.117.033502. Review.

PMID:
29483172
9.

Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach.

Doros G, Massaro JM, Kandzari DE, Waksman R, Koolen JJ, Cutlip DE, Mauri L.

Am Heart J. 2017 Nov;193:35-45. doi: 10.1016/j.ahj.2017.08.001. Epub 2017 Aug 5.

PMID:
29129253
10.

Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention.

Yeh RW, Kereiakes DJ, Steg PG, Cutlip DE, Croce KJ, Massaro JM, Mauri L; DAPT Study Investigators.

J Am Coll Cardiol. 2017 Oct 31;70(18):2213-2223. doi: 10.1016/j.jacc.2017.09.011.

11.

Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.

Kandzari DE, Mauri L, Koolen JJ, Massaro JM, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R; BIOFLOW V Investigators.

Lancet. 2017 Oct 21;390(10105):1843-1852. doi: 10.1016/S0140-6736(17)32249-3. Epub 2017 Aug 26. Erratum in: Lancet. 2017 Oct 21;390(10105):1832.

PMID:
28851504
12.

Factors associated with performing urgent coronary angiography in out-of-hospital cardiac arrest patients.

Lam DH, Glassmoyer LM, Strom JB, Davis RB, McCabe JM, Cutlip DE, Donnino MW, Cocchi MN, Pinto DS.

Catheter Cardiovasc Interv. 2018 Apr 1;91(5):832-839. doi: 10.1002/ccd.27199. Epub 2017 Aug 2.

PMID:
28766924
13.

Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing evaluation: Rationale and best practices. A report from the cardiac safety research consortium.

Seltzer JH, Heise T, Carson P, Canos D, Hiatt JC, Vranckx P, Christen T, Cutlip DE.

Am Heart J. 2017 Aug;190:76-85. doi: 10.1016/j.ahj.2017.05.009. Epub 2017 May 28. Review.

PMID:
28760216
14.

Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.

Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Steg PG, Massaro JM, Apruzzese PK, Mauri L; Dual Antiplatelet Therapy Study Investigators.

JACC Cardiovasc Interv. 2017 May 8;10(9):942-954. doi: 10.1016/j.jcin.2017.02.013.

15.

Clinical Trial Principles and Endpoint Definitions for Paravalvular Leaks in Surgical Prosthesis.

Ruiz CE, Hahn RT, Berrebi A, Borer JS, Cutlip DE, Fontana G, Gerosa G, Ibrahim R, Jelnin V, Jilaihawi H, Jolicoeur EM, Kliger C, Kronzon I, Leipsic J, Maisano F, Millan X, Nataf P, O'Gara PT, Pibarot P, Ramee SR, Rihal CS, Rodes-Cabau J, Sorajja P, Suri R, Swain JA, Turi ZG, Tuzcu EM, Weissman NJ, Zamorano JL, Serruys PW, Leon MB; Paravalvular Leak Academic Research Consortium.

Eur Heart J. 2018 Apr 14;39(15):1224-1245. doi: 10.1093/eurheartj/ehx211.

PMID:
28430909
16.

Clinical Trial Principles and Endpoint Definitions for Paravalvular Leaks in Surgical Prosthesis: An Expert Statement.

Ruiz CE, Hahn RT, Berrebi A, Borer JS, Cutlip DE, Fontana G, Gerosa G, Ibrahim R, Jelnin V, Jilaihawi H, Jolicoeur EM, Kliger C, Kronzon I, Leipsic J, Maisano F, Millan X, Nataf P, O'Gara PT, Pibarot P, Ramee SR, Rihal CS, Rodes-Cabau J, Sorajja P, Suri R, Swain JA, Turi ZG, Tuzcu EM, Weissman NJ, Zamorano JL, Serruys PW, Leon MB; Paravalvular Leak Academic Research Consortium.

J Am Coll Cardiol. 2017 Apr 25;69(16):2067-2087. doi: 10.1016/j.jacc.2017.02.038. Review.

17.

Cigarette smoking and cardio-renal events in patients with atherosclerotic renal artery stenosis.

Drummond CA, Brewster PS, He W, Ren K, Xie Y, Tuttle KR, Haller ST, Jamerson K, Dworkin LD, Cutlip DE, Murphy TP, D'Agostino RB Sr, Henrich WL, Tian J, Shapiro JI, Cooper CJ.

PLoS One. 2017 Mar 17;12(3):e0173562. doi: 10.1371/journal.pone.0173562. eCollection 2017.

18.

Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study.

Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Cohen DJ, Steg PG, Cannon CP, Apruzzese PK, D'Agostino RB Sr, Massaro JM, Mauri L; Dual Antiplatelet Therapy (DAPT) Study Investigators.

JAMA Cardiol. 2017 May 1;2(5):478-487. doi: 10.1001/jamacardio.2017.0063.

19.

Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).

Stefanescu Schmidt AC, Kereiakes DJ, Cutlip DE, Yeh RW, D'Agostino RB Sr, Massaro JM, Hsieh WH, Mauri L; DAPT Investigators.

Circulation. 2017 May 2;135(18):1720-1732. doi: 10.1161/CIRCULATIONAHA.116.024835. Epub 2017 Feb 22.

20.

Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative.

Lansky AJ, Messé SR, Brickman AM, Dwyer M, van der Worp HB, Lazar RM, Pietras CG, Abrams KJ, McFadden E, Petersen NH, Browndyke J, Prendergast B, Ng VG, Cutlip DE, Kapadia S, Krucoff MW, Linke A, Moy CS, Schofer J, van Es GA, Virmani R, Popma J, Parides MK, Kodali S, Bilello M, Zivadinov R, Akar J, Furie KL, Gress D, Voros S, Moses J, Greer D, Forrest JK, Holmes D, Kappetein AP, Mack M, Baumbach A.

J Am Coll Cardiol. 2017 Feb 14;69(6):679-691. doi: 10.1016/j.jacc.2016.11.045. Review.

21.

Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative.

Lansky AJ, Messé SR, Brickman AM, Dwyer M, Bart van der Worp H, Lazar RM, Pietras CG, Abrams KJ, McFadden E, Petersen NH, Browndyke J, Prendergast B, Ng VG, Cutlip DE, Kapadia S, Krucoff MW, Linke A, Scala Moy C, Schofer J, van Es GA, Virmani R, Popma J, Parides MK, Kodali S, Bilello M, Zivadinov R, Akar J, Furie KL, Gress D, Voros S, Moses J, Greer D, Forrest JK, Holmes D, Kappetein AP, Mack M, Baumbach A.

Eur Heart J. 2018 May 14;39(19):1687-1697. doi: 10.1093/eurheartj/ehx037.

PMID:
28171522
22.

9-Month Clinical and Angiographic Outcomes of the COBRA Polyzene-F NanoCoated Coronary Stent System.

Cutlip DE, Garratt KN, Novack V, Barakat M, Meraj P, Maillard L, Erglis A, Jauhar R, Popma JJ, Stoler R, Silber S; PzF SHIELD Trial Investigators.

JACC Cardiovasc Interv. 2017 Jan 23;10(2):160-167. doi: 10.1016/j.jcin.2016.10.037.

23.

Relationship of Albuminuria and Renal Artery Stent Outcomes: Results From the CORAL Randomized Clinical Trial (Cardiovascular Outcomes With Renal Artery Lesions).

Murphy TP, Cooper CJ, Pencina KM, D'Agostino R, Massaro J, Cutlip DE, Jamerson K, Matsumoto AH, Henrich W, Shapiro JI, Tuttle KR, Cohen DJ, Steffes M, Gao Q, Metzger DC, Abernethy WB, Textor SC, Briguglio J, Hirsch AT, Tobe S, Dworkin LD.

Hypertension. 2016 Nov;68(5):1145-1152. Epub 2016 Sep 19.

24.

Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study.

Resor CD, Nathan A, Kereiakes DJ, Yeh RW, Massaro JM, Cutlip DE, Gabriel Steg P, Hsieh WH, Mauri L; Dual Antiplatelet Therapy Study Investigators.

Circulation. 2016 Oct 4;134(14):989-998. Epub 2016 Aug 30.

25.

Accreditation and funding for a 24-month advanced interventional cardiology fellowship program: A call-to-action for optimal training of the next generation of interventionalists.

Kalra A, Bhatt DL, Pinto DS, Kirtane AJ, Kapadia SR, Makkar RR, Rihal CS, Kleiman NS, Cutlip DE.

Catheter Cardiovasc Interv. 2016 Nov 15;88(6):1010-1015. doi: 10.1002/ccd.26661. Epub 2016 Aug 12. No abstract available.

PMID:
27515241
26.

Dedicated Bifurcation Stent for the Treatment of Bifurcation Lesions Involving Large Side Branches: Outcomes From the Tryton Confirmatory Study.

Généreux P, Kumsars I, Schneider JE, Lesiak M, Redfors B, Cornelis K, Selmon MR, Dens J, Hoye A, Metzger DC, Muyldermans L, Slagboom T, Francese DP, Ayele GM, Laak LL, Bartorelli AL, Cutlip DE, Kaplan AV, Leon MB.

JACC Cardiovasc Interv. 2016 Jul 11;9(13):1338-46. doi: 10.1016/j.jcin.2016.03.042.

27.

Adapting DAPT to Improve Outcomes After Coronary Stenting.

Cutlip DE.

JACC Cardiovasc Interv. 2016 Jul 25;9(14):1458-60. doi: 10.1016/j.jcin.2016.05.027. Epub 2016 Jun 29. No abstract available.

28.

Effects of Stenting for Atherosclerotic Renal Artery Stenosis on eGFR and Predictors of Clinical Events in the CORAL Trial.

Tuttle KR, Dworkin LD, Henrich W, Greco BA, Steffes M, Tobe S, Shapiro JI, Jamerson K, Lyass A, Pencina K, Massaro JM, D'Agostino RB Sr, Cutlip DE, Murphy TP, Cooper CJ.

Clin J Am Soc Nephrol. 2016 Jul 7;11(7):1180-8. doi: 10.2215/CJN.10491015. Epub 2016 May 25.

29.

Value-Based Hypothesis Testing for Cardiac Device Clinical Trials: A Pathway for Accelerated Reimbursement Decisions.

Cutlip DE, Kramer DB.

Circ Cardiovasc Interv. 2016 May;9(5):e003627. doi: 10.1161/CIRCINTERVENTIONS.116.003627. No abstract available.

30.

DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction.

Kereiakes DJ, Yeh RW, Massaro JM, Cutlip DE, Steg PG, Wiviott SD, Mauri L; DAPT Study Investigators.

J Am Coll Cardiol. 2016 May 31;67(21):2492-502. doi: 10.1016/j.jacc.2016.03.485. Epub 2016 Apr 1.

31.

Should We Screen for Coronary Heart Disease in Asymptomatic Persons?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.

Smetana GW, Cutlip DE, Pinto DS.

Ann Intern Med. 2016 Apr 5;164(7):479-87. doi: 10.7326/M15-2910.

PMID:
27043981
32.

Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.

Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L; DAPT Study Investigators.

JAMA. 2016 Apr 26;315(16):1735-49. doi: 10.1001/jama.2016.3775. Erratum in: JAMA. 2016 Jul 19;316(3):350. Erratum in: JAMA. 2016 Jul 19;316(3):350.

33.

Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study.

Meredith IT, Tanguay JF, Kereiakes DJ, Cutlip DE, Yeh RW, Garratt KN, Lee DP, Steg PG, Weaver WD, Holmes DR Jr, Brindis RG, Trebacz J, Massaro JM, Hsieh WH, Mauri L; DAPT Study Investigators.

Circulation. 2016 May 3;133(18):1772-82. doi: 10.1161/CIRCULATIONAHA.115.016783. Epub 2016 Mar 18. Erratum in: Circulation. 2016 May 31;133(22):e671.

PMID:
26994121
34.

Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.

Hermiller JB, Krucoff MW, Kereiakes DJ, Windecker S, Steg PG, Yeh RW, Cohen DJ, Cutlip DE, Massaro JM, Hsieh WH, Mauri L; DAPT Study Investigators.

JACC Cardiovasc Interv. 2016 Jan 25;9(2):138-47. doi: 10.1016/j.jcin.2015.10.001.

35.

Utility of a real-time appropriate use criteria decision support application for percutaneous coronary interventions in non-acute coronary syndrome.

Chen SH, Ho KK, Gannon SA, Thyagarajan B, Chakrabarti AK, Potter BJ, Singla A, Piccirillo BJ, Meduri CU, Cutlip DE.

Catheter Cardiovasc Interv. 2016 Sep;88(3):E74-9. doi: 10.1002/ccd.26350. Epub 2015 Dec 23.

PMID:
26699241
36.

Renal Artery Stent Outcomes: Effect of Baseline Blood Pressure, Stenosis Severity, and Translesion Pressure Gradient.

Murphy TP, Cooper CJ, Matsumoto AH, Cutlip DE, Pencina KM, Jamerson K, Tuttle KR, Shapiro JI, D'Agostino R, Massaro J, Henrich W, Dworkin LD.

J Am Coll Cardiol. 2015 Dec 8;66(22):2487-94. doi: 10.1016/j.jacc.2015.09.073.

37.

Carotid angiographic characteristics in the CREST trial were major contributors to periprocedural stroke and death differences between carotid artery stenting and carotid endarterectomy.

Moore WS, Popma JJ, Roubin GS, Voeks JH, Cutlip DE, Jones M, Howard G, Brott TG; CREST Investigators.

J Vasc Surg. 2016 Apr;63(4):851-7, 858.e1. doi: 10.1016/j.jvs.2015.08.119. Epub 2015 Nov 21.

38.

Causes of late mortality with dual antiplatelet therapy after coronary stents.

Mauri L, Elmariah S, Yeh RW, Cutlip DE, Steg PG, Windecker S, Wiviott SD, Cohen DJ, Massaro JM, D'Agostino RB Sr, Braunwald E, Kereiakes DJ; DAPT Study Investigators.

Eur Heart J. 2016 Jan 21;37(4):378-85. doi: 10.1093/eurheartj/ehv614. Epub 2015 Nov 18.

39.

Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy.

Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L; DAPT Study Investigators.

JACC Cardiovasc Interv. 2015 Oct;8(12):1552-62. doi: 10.1016/j.jcin.2015.05.026. Erratum in: JACC Cardiovasc Interv. 2015 Dec 21;8(14):1913.

40.

The effect of gender on outcomes of aortoiliac artery interventions for claudication.

Krishnamurthy VN, Naeem M, Murphy TP, Cerezo J, Jordan PG, Goldberg SH, Ershow AG, Hirsch AT, Oldenburg N, Cutlip DE.

Clin Imaging. 2016 Jan-Feb;40(1):96-100. doi: 10.1016/j.clinimag.2015.09.003. Epub 2015 Sep 4.

41.

Outcomes of a dedicated stent in coronary bifurcations with large side branches: A subanalysis of the randomized TRYTON bifurcation study.

Généreux P, Kini A, Lesiak M, Kumsars I, Fontos G, Slagboom T, Ungi I, Metzger DC, Wykrzykowska JJ, Stella PR, Bartorelli AL, Fearon WF, Lefèvre T, Feldman RL, Tarantini G, Bettinger N, Minalu Ayele G, LaSalle L, Francese DP, Onuma Y, Grundeken MJ, Garcia-Garcia HM, Laak LL, Cutlip DE, Kaplan AV, Serruys PW, Leon MB.

Catheter Cardiovasc Interv. 2016 Jun;87(7):1231-41. doi: 10.1002/ccd.26240. Epub 2015 Sep 23.

PMID:
26397982
42.

2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).

Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, Fonarow GC, Jacobs JP, Jaff MR, Lichtman JH, Limacher MC, Mahaffey KW, Mehran R, Nissen SE, Smith EE, Targum SL; ACC/AHA TASK FORCE ON CLINICAL DATA STANDARDS MEMBERS.

J Nucl Cardiol. 2015 Oct;22(5):1041-144. doi: 10.1007/s12350-015-0209-1. No abstract available.

PMID:
26204990
43.

Regulatory science: Trust and transparency in clinical trials of medical devices.

Kramer DB, Cutlip DE.

Nat Rev Cardiol. 2015 Sep;12(9):503-4. doi: 10.1038/nrcardio.2015.112. Epub 2015 Jul 21. No abstract available.

44.

Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles: A Consensus Document From the Mitral Valve Academic Research Consortium.

Stone GW, Vahanian AS, Adams DH, Abraham WT, Borer JS, Bax JJ, Schofer J, Cutlip DE, Krucoff MW, Blackstone EH, Généreux P, Mack MJ, Siegel RJ, Grayburn PA, Enriquez-Sarano M, Lancellotti P, Filippatos G, Kappetein AP; Mitral Valve Academic Research Consortium (MVARC).

J Am Coll Cardiol. 2015 Jul 21;66(3):278-307. doi: 10.1016/j.jacc.2015.05.046.

45.

Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles: A consensus document from the mitral valve academic research consortium.

Stone GW, Vahanian AS, Adams DH, Abraham WT, Borer JS, Bax JJ, Schofer J, Cutlip DE, Krucoff MW, Blackstone EH, Généreux P, Mack MJ, Siegel RJ, Grayburn PA, Enriquez-Sarano M, Lancellotti P, Filippatos G, Kappetein AP; Mitral Valve Academic Research Consortium (MVARC).

Eur Heart J. 2015 Aug 1;36(29):1851-77. doi: 10.1093/eurheartj/ehv281. Epub 2015 Jul 13. Review.

46.

Regional and physician specialty-associated variations in the medical management of atherosclerotic renal-artery stenosis.

Folt DA, Evans KL, Brahmandam S, He W, Brewster PS, Yu S, Murphy TP, Cutlip DE, Dworkin LD, Jamerson K, Henrich W, Kalra PA, Tobe S, Thomson K, Holden A, Rayner BL, Grinfeld L, Haller ST, Cooper CJ.

J Am Soc Hypertens. 2015 Jun;9(6):443-52. doi: 10.1016/j.jash.2015.03.007. Epub 2015 Mar 28.

47.

A 54-year-old woman with a single coronary artery and watershed ischemia treated with nitrates.

Melman YF, Cutlip DE, Das S.

JACC Cardiovasc Interv. 2015 May;8(6):e91-e94. doi: 10.1016/j.jcin.2014.12.248. Epub 2015 Apr 22. No abstract available.

48.

Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction.

Yeh RW, Kereiakes DJ, Steg PG, Windecker S, Rinaldi MJ, Gershlick AH, Cutlip DE, Cohen DJ, Tanguay JF, Jacobs A, Wiviott SD, Massaro JM, Iancu AC, Mauri L; DAPT Study Investigators.

J Am Coll Cardiol. 2015 May 26;65(20):2211-21. doi: 10.1016/j.jacc.2015.03.003. Epub 2015 Mar 15.

49.

Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial.

Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L; Dual Antiplatelet Therapy (DAPT) Study Investigators.

JAMA. 2015 Mar 17;313(11):1113-21. doi: 10.1001/jama.2015.1671. Erratum in: JAMA. 2016 Jul 5;316(1):105. JAMA. 2016 Jul 5;316(1):105. JAMA. 2015 Jun 2;313(21):2185.

50.

Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study.

Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER 3rd, Cohen DJ, Reynolds MR, Massaro JM, Lewis BA, Cerezo J, Oldenburg NC, Thum CC, Jaff MR, Comerota AJ, Steffes MW, Abrahamsen IH, Goldberg S, Hirsch AT.

J Am Coll Cardiol. 2015 Mar 17;65(10):999-1009. doi: 10.1016/j.jacc.2014.12.043. Erratum in: J Am Coll Cardiol. 2015 May 12;65(18):2055.

Supplemental Content

Loading ...
Support Center